FDA grants Janssen/J&J drug Stelara OK in psoriatic arthritis
This article was originally published in Scrip
Executive Summary
Johnson & Johnson's US subsidiary Janssen Biotech on 23 September said it won the FDA's blessing to market Stelara (ustekinumab) alone or in combination with methotrexate as a treatment for adults with active psoriatic arthritis, a chronic autoimmune disease characterized by both joint inflammation and psoriasis skin lesions.